Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Argen-X B.V.. (5/28/14). "Press Release: Argen-X Announces Collaboration with Bayer to Discover and Develop Therapeutic Antibody Candidates". Breda.

Organisation Organisation Argen-X B.V.
  Today Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Group Argen-X (Argenx) (Group)
Products Product SIMPLE Antibody™ discovery platform
  Product 2 therapeutic antibody
Index term Index term Bayer–Argen-X: antibody technology, 201405– collab use of SIMPLE Antibody platform to discover + develop therap antibodies against Bayer targets
Persons Person Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)
  Person 2 Dinter, Harald (Bayer 201405 Head of Global Biologics at Bayer Pharma AG)
     


arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X's SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms.

"We are delighted that Bayer, with its long-standing expertise in drug development, will make use of the SIMPLE Antibody™ platform. As a company, we are dedicated to forming elite partnerships and feel that with this new collaboration, we have firmly established SIMPLE Antibody™ as an innovative solution to reaching intractable targets and tackling unmet needs in antibody discovery," said Tim Van Hauwermeiren, Chief Executive Officer of arGEN-X. "We are confident that by building on our proprietary capabilities in DNA immunization and the unique immune system of the llama, we have developed a novel platform that will create potential new product opportunities."

With this collaboration, arGEN-X will apply its SIMPLE Antibody™ technology to multiple targets submitted by Bayer. The parties will work together to validate human antibody leads in disease-relevant models, with Bayer being responsible for further preclinical and clinical development and commercialization of therapeutic antibody products. Under the terms of the Agreement, Bayer will pay arGEN-X an upfront technology access fee, research support and technical success-based milestones. Bayer will also pay clinical, regulatory and product sales-based milestones as antibody programs progress through clinical development and registration.

"We look forward to collaborating with arGEN-X and exploring the potential of SIMPLE Antibody™ technology to complement Bayer's efforts in the discovery and development of first-in-class therapeutic antibodies," said Dr. Harald Dinter, Head of Global Biologics at Bayer Pharma AG.


About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody candidates using its SIMPLE Antibody™ discovery platform. SIMPLE Antibody™ has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Fc engineering technologies - NHance®, ABDEG™ and POTELLIGENT® - further enhance the therapeutic properties of SIMPLE Antibody™ leads in terms of their residence time in the body, their ability to clear disease targets or pathogenic antibodies and their cell killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.

http://www.arGEN-X.com


For further information, please contact:

Tim Van Hauwermeiren
Chief Executive Officer
+32(0)9-243-40-70

Debbie Allen
VP Business Development
+44(0)7974-979479

info@arGEN-X.com

Mark Swallow/David Dible
Citigate Dewe Rogerson
+44(0)207-282-2949
arGEN-X@citigatedr.co.uk

Beth DelGiacco
Stern Investor Relations
+1-212-362-1200
beth@sternir.com

   
Record changed: 2017-04-02

Advertisement

Picture Lipotype Lipidomics Drug Biomarker Discovery iito 600x60px

More documents for Argen-X (Argenx) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top